February 14, 2018 / 1:26 PM / in 3 months

BRIEF-Athenex Says Patient Enrollment For Two Late Stage Studies Of Actinic Keratosis Treatment Completed

Reuters Staff

1 Min Read

Feb 14 (Reuters) - Athenex Inc:

* ATHENEX ANNOUNCES EARLY COMPLETION OF PATIENTS ENROLLMENT FOR TWO PHASE III CLINICAL STUDIES OF KX2-391 OINTMENT FOR ACTINIC KERATOSIS Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below